DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Recruiting now · Phase 2

Conditions studied: Hepatocellular Carcinoma Non-resectable

In brief

This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed (RALOX-HAIC) versus DEB-TACE alone for unresectable large hepatocellular carcinoma (HCC).

Key facts

Study ID
NCT06397235
Run by
Second Affiliated Hospital of Guangzhou Medical University
People needed
130
Starts
2024-05-01
Expected to finish
2028-04-30
Last updated by the study team
2025-02-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.